Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28325117 | 0.86 | MAOB (0.56) | MAOBSGMS2IMPDH2MAOAHPGD | |
| SCHEMBL23218707 | 0.83 | HSD17B10 (0.50) | THRBHPGDMAPTTSHRHSD17B10 | |
| SCHEMBL29592548 | 0.83 | HSD17B10 (0.50) | THRBHPGDMAPTTSHRHSD17B10 | |
| SCHEMBL1154801 | 0.82 | THRB (0.56) | MAOBTHRATHRBMAOAHPGD | |
| SCHEMBL15602827 | 0.82 | SGMS2 (0.52) | MAOBSGMS2MAPTMAPK1TDP1 | |
| SCHEMBL28326121 | 0.81 | MAOB (0.51) | MAOBTHRATHRBSGMS2IMPDH2 | |
| SCHEMBL450088 | 0.81 | KDM1A (0.50) | MAOBSGMS2IMPDH2MAOAHPGD | |
| SCHEMBL2445589 | 0.80 | MAOB (0.50) | MAOBTHRATHRBSGMS2IMPDH2 | |
| SCHEMBL16719426 | 0.78 | MAOB (0.49) | MAOBSGMS2IMPDH2HPGDMAPT | |
| SCHEMBL8409148 | 0.78 | HTR1A (0.53) | MAOBSGMS2IMPDH2FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199993-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199993-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8802698-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802698-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2183249-B1 | 8-Azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8481563-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2183249-A1 | 8-AZABICYCLOÝ3.2.1¨OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009029256-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-05 | — | — | US | disclosed |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-05 | — | — | US | disclosed |
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | MARQUIS ROBERT W | 2008-09-25 | — | — | US | disclosed |
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | MARQUIS ROBERT W | 2008-09-25 | — | — | US | disclosed |
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | MARQUIS ROBERT W | 2008-09-25 | — | — | US | disclosed |
| EP-1713767-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1713767-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077892-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | PTH1R, CASR, CALCR | MAOB 4815/4885THRA 55/4885THRB 155/4885 |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | MAOB 110/4885THRA 458/4885THRB 239/4885 |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | MAOB 110/4885THRA 458/4885THRB 239/4885 |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | MAOB 110/4885THRA 458/4885THRB 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.